• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SeaSpine Announces Full Commercial Launch of the 7D FLASH™ Navigation System Percutaneous Spine Module for Minimally Invasive Surgery

    10/18/22 4:10:00 PM ET
    $SPNE
    Medical Specialities
    Health Care
    Get the next $SPNE alert in real time by email

    CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the 7D FLASH™ Navigation System Percutaneous Spine Module. The release of the Percutaneous Module represents a new application and increased functionality for its 7D FLASH Navigation System, which now allows SeaSpine to further penetrate the minimally invasive spine surgery market, which SeaSpine estimates at approximately $4 billion worldwide.

    "The addition of the Percutaneous Module to the FLASH Navigation System has brought versatility to my OR," stated Dr. Douglas Orndorff of Spine Colorado.  "Whether I am performing mini-open procedures, large revision surgeries, or MIS fusions, I can do them all with one system that optimizes my workflows depending on my approach.  I'm also excited about the future launch of the Lumbar Facet Fusion system that will work seamlessly with the Percutaneous Module, enabling an integrated procedural solution for my patients."

    The 7D FLASH Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing frustrations with legacy surgical navigation platforms. The speed, accuracy, and efficiency of machine-vision technology is intended to provide significant economic value, lower radiation for staff and patients in open procedures, and harnesses the true potential of image-guided navigation – providing a truly unique offering for both open and minimally invasive spine procedures.

    "Our Percutaneous Module has expanded the clinical functionality of the FLASH Navigation System by providing surgeons with a fully integrated procedural solution for minimally invasive surgery," said Dr. Beau Standish, President of Enabling Technologies at SeaSpine. "This new application addresses a large and important part of the spine navigation market and should help drive adoption of our FLASH Navigation System among surgeons, hospitals and ambulatory surgery centers."

    About SeaSpine

    SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine's complete procedural solutions feature its market-leading FLASH™ Navigation, a system designed to improve accuracy of screw placement and provide a cost-effective, rapid, radiation-free solution to surgical navigation, and a comprehensive portfolio of spinal implants and orthobiologics to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures on the lumbar, thoracic and cervical spine. With product development expertise in advanced optics, software, orthobiologic sciences and spinal implants, SeaSpine can offer its surgeon customers a complete solution to meet their patients' evolving clinical needs. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.

    Forward-Looking Statements

    SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the future launch of the Company's Lumbar Facet Fusion system and its ability to work with the Percutaneous Module; the expectation that the 7D FLASH Navigation System will result in shorter and more efficient spinal procedures; the ability of the 7D FLASH Navigation System to eliminate the long-standing frustrations with legacy surgical navigation platforms and to provide significant economic value and harnesses the true potential of image-guided navigation in surgical procedures; and the ability of the 7D Percutaneous Spine Module to help drive adoption of the FLASH Navigation System among surgeons, hospitals and ambulatory surgery centers.   Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of the 7D FLASH Navigation System to perform as designed and intended and to meet the needs of surgeons and patients; risks inherent in the use of novel imaging techniques, including advanced optical technologies and machine vision-based registration algorithms; unexpected delays in the support and/or launch of the 7D Percutaneous Spine Module or other next generation or new applications of the 7D FLASH Navigation System, including the fact that newly launched products may require substantial additional development activities, which could introduce further delays, or as a result of obtaining regulatory clearances; and other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

    You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

    Investor Relations Contact

    Greg Chodaczek

    610-368-6505

    [email protected]



    Primary Logo

    Get the next $SPNE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SPNE

    DatePrice TargetRatingAnalyst
    11/2/2022$12.00 → $6.75Buy → Hold
    Truist
    4/22/2022$27.00 → $21.00Overweight
    Cantor Fitzgerald
    4/13/2022$20.00Buy
    Truist
    12/21/2021$25.00 → $20.00Buy
    Truist Securities
    10/28/2021$100.00Buy
    Loop Capital
    More analyst ratings

    $SPNE
    SEC Filings

    See more
    • SEC Form CT ORDER filed by SeaSpine Holdings Corporation

      CT ORDER - SeaSpine Holdings Corp (0001637761) (Filer)

      4/3/23 8:19:25 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by SeaSpine Holdings Corporation

      15-12G - SeaSpine Holdings Corp (0001637761) (Filer)

      1/17/23 4:31:53 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by SeaSpine Holdings Corporation

      EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)

      1/12/23 12:15:22 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Leadership Updates

    Live Leadership Updates

    See more
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team. Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influentia

      5/3/22 4:04:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants. With his promotion, Mr. Bannigan joins the SeaSpine Senior Leadership Team. Dr. Vizesi joined SeaSpine in 2015 as Director, Research and Development, Orthobiologics. He quickly elevated the approach and defined the vision for delivering best-in-class orthobiologics procedural solutions. Under Dr. Vizesi's leadership, the team deepened

      3/7/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

      CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent. Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she i

      12/14/21 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:21:07 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:51 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:35 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SeaSpine downgraded by Truist with a new price target

      Truist downgraded SeaSpine from Buy to Hold and set a new price target of $6.75 from $12.00 previously

      11/2/22 6:34:40 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Cantor Fitzgerald resumed coverage on SeaSpine with a new price target

      Cantor Fitzgerald resumed coverage of SeaSpine with a rating of Overweight and set a new price target of $21.00 from $27.00 previously

      4/22/22 9:10:58 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Truist resumed coverage on SeaSpine with a new price target

      Truist resumed coverage of SeaSpine with a rating of Buy and set a new price target of $20.00

      4/13/22 7:17:39 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System

      CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru

      12/27/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $SPNE
    Financials

    Live finance-specific insights

    See more
    • SeaSpine to Report Third Quarter 2022 Financial Results on November 1, 2022

      CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des

      10/24/22 7:00:00 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

      Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin

      10/11/22 6:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • SeaSpine Reports 19% Revenue Growth and Record Quarterly Revenue for Second Quarter 2022 and Raises Full Year 2022 Revenue Guidance

      CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today second quarter financial results for the three-months ended June 30, 2022. Summary Second Quarter 2022 Financial Results and Recent Highlights Total revenue of $56.3 million, an increase of 19% year-over-yearU.S. revenue of $49.5 million, an increase of 16% year-over-year U.S. spinal implants and enabling technologies revenue of $25.0 million, an increase of 17% year-over-yearU.S. orthobiologics revenue of $24.5 million, an increase of 16% year-over-year International reve

      8/2/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      1/31/23 1:58:01 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/14/22 11:45:59 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/3/22 4:41:28 PM ET
      $SPNE
      Medical Specialities
      Health Care